more_reports

Rakovina Therapeutics Inc.

RKV:TSX.V;RKVTF:OTCPK;7JO0:FSE

streetwise book logo Streetwise Company Fact Sheet

Company News 

11/12/2026 – Rakovina Therapeutics Expands Strategic Engagement with Renowned AI Drug Discovery Pioneer Dr. Artem Cherkasov

11/10/2026 – Rakovina Therapeutics Secures Exclusive Worldwide Licence to Artemis.AI(TM) Platform for DNA-Damage Response Oncology Drug Discovery

10/28/2026 – Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program

10/22/2026 – Rakovina Therapeutics and Variational AI Advance Brain-Penetrant ATR Program Toward Development Candidate Selection

10/14/2026 – Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI

10/1/2026 – Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development

8/31/2026 – Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update

8/31/2026 – Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement

8/19/2026 – Rakovina Therapeutics Announces Results from 2026 Annual General Meeting